The HPV Data Is In — What Do the Newest Updates in Screening Mean For Your Patients?

ReachMD Healthcare Image
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    The Cervical Cancer Screening practice environment continues to change for both physicians and patients. Physicians are constantly tasked with evaluating analyses of new data on how best to approach cervical cancer screening for a particular patient demographic; and patients remain confused and unsure if the “new” approaches are better, or even less safe, than the “Pap” that has served as the bedrock for so many years.

    This activity previously aired as a ReachMD Live Broadcast, where Dr. Thomas Wright, Jr., addressed these wide-ranging issues in a real-time, question and answer forum.

    THIS ACTIVITY IS NO LONGER AVAILABLE FOR CME CREDIT.

  • Disclaimer

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Jennifer Caudle, DO
    Family Medicine Physician and Assistant Professor
    Department of Family Medicine
    Rowan University-School of Osteopathic Medicine
    Stratford, New Jersey

    Dr. Caudle has no financial relationships to disclose. 

    Faculty:
    Thomas C. Wright, Jr., MD
    Professor Emeritus of Pathology and Cell Biology
    Columbia University
    New York, NY

    Dr. Wright receives consulting fees from Abbott, BD, and Roche; and contracted research from BD, Inovio, and Roche. 

    Reviewers/Planners/Authors:  

    • Sean T. Barrett has nothing to disclose.
    • Carole Drexel, PhD has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Summarize the emergent USPSTF draft recommendations and their potential impact toward a more unified strategy for cervical cancer screening and triage in the US.
    2. Analyze the growing real-world experience with primary HPV screening as the preferred approach when assessing a woman's risk for developing cervical cancer to facilitate its adoption in US practices as recommended by the USPSTF.
    3. Formulate strategies to manage discussions with patients when addressing the duration period between cervical cancer screenings.
  • Target Audience

    This activity is designed to meet the educational needs of the obstetrician and gynecologist, family physician, internal medicine physician, physician assistant, nurse practitioner, and certified nurse midwife.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

    ReachMD Healthcare Image

  • Commercial Support

    This activity is supported by an independent educational grant from Roche Diagnostics.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

NEW FEATURES:

Register

We're glad to see you're enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free